Free Trial
NASDAQ:TELA

TELA Bio Q3 2025 Earnings Report

TELA Bio logo
$1.48 -0.05 (-3.27%)
Closing price 04:00 PM Eastern
Extended Trading
$1.47 -0.01 (-0.68%)
As of 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TELA Bio EPS Results

Actual EPS
N/A
Consensus EPS
-$0.17
Beat/Miss
N/A
One Year Ago EPS
N/A

TELA Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
$21.78 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

TELA Bio Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

TELA Bio Earnings Headlines

Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.tc pixel
Positive Signs As Multiple Insiders Buy TELA Bio Stock
TELA Bio’s Earnings Call Highlights Robust Growth
See More TELA Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TELA Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TELA Bio and other key companies, straight to your email.

About TELA Bio

TELA Bio (NASDAQ:TELA) (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems. Its flagship offering, TELAPro™, is an acellular dermal matrix designed for abdominal wall reconstruction and complex soft tissue repair. In addition, TELA Bio markets fibrin sealant systems and surgical films that serve as adjunctive tools for hemostasis and tissue regeneration across a variety of surgical and wound care settings.

Operating primarily in the United States, TELA Bio collaborates with surgeons, wound care specialists and research institutions to advance clinical protocols and broaden the applications of its platform technologies. Its manufacturing facility in Plymouth, Minnesota, adheres to rigorous quality and regulatory standards, supporting scalable production. Guided by a leadership team experienced in medical devices, biomaterials and commercial operations, TELA Bio is focused on expanding clinical adoption and growing its product pipeline in the regenerative medicine market.

View TELA Bio Profile

More Earnings Resources from MarketBeat